ERBB2 and breast carcinoma: In two landmark adjuvant trastuzumab trials including patients with HER2-amplified or overexpressing breast cancer according to local site laboratories, a cohort of patients with neither HER2-amplification nor HER2 overexpression by central testing was identified.